汪凯，男，湖北武汉人，副研究员，博士生导师。2012年毕业于中国科学院上海巴斯德研究所，获理学博士学位。硕博连读期间主要从事病毒离子通道研究及抗病毒药物筛选。2015年就职于重庆医科大学，目前主要从事分子病毒学及肝癌代谢研究；围绕代谢与信号转导的交互调控，旨在揭示代谢重编程在肝癌发生发展中的作用，为肝癌治疗提供新的靶点。重医未来医学青年创新团队“病毒感染与代谢重塑研究团队”负责人，先后主持国家自然科学基金3项，重庆市科委及教委课题4项，重庆医科大学“新冠肺炎”应急课题；作为技术骨干参与国家重点研发计划等项目。在国内外期刊发表学术论文80余篇，其中以第一作者或通讯作者（含共同）在Clinical Infectious Diseases、Cell Metabolism、Journal of Clinical Investigation、EMBO J、Cell Research、Nature Communications和Signal Transduct Target Ther等期刊发表SCI论文40余篇（含ESI高被引3篇），总引用2800余次，H指数29。入选Elsevier中国金色开放获取高下载论文学者（2020-2021生命科学领域），获2023川渝科学技术学术大会优秀论文特等奖、重庆市期刊优秀论文一等奖、国家发明专利1项。任中国抗癌协会肿瘤代谢专委会青年委员、重庆抗癌协会化疗专业委员会委员，Advanced Science、Nat Commun等期刊审稿专家。

ORCID: https://orcid.org/0000-0002-0137-1247

工作经历

2020.10 - 至今    重庆医科大学  感染性疾病分子生物学重点实验室   副研究员

2019.10 - 2020.09  重庆医科大学  感染性疾病分子生物学重点实验室   副教授

2015.09 - 2019.09  重庆医科大学  基础医学院  病原生物学教研室    讲师

2013.07 - 2015.07  中国科学院   上海生命科学研究院           博士后

2012.05 - 2013.05  中科院上海巴斯德研究所分子病毒与免疫重点实验室  助理研究员

研究方向

(1)分子病毒学——感染与代谢重塑；

(2)代谢重编程调控肝癌发生发展的分子机制研究。

学术任职

中国抗癌协会肿瘤代谢专委会青年委员；

重庆抗癌协会化疗专业委员会委员；

Advanced Science、Nat Commun、Clin Transl Med、Genes & Diseases等学术期刊审稿人。

奖励荣誉

2021年 重庆医科大学“优秀科技成果奖”

2021年 爱思唯尔Elsevier“中国金色开放获取高下载论文学者”

2021年 第二十一届重庆市期刊优秀论文 年度优秀论文 一等奖 

2023年 MCE中国生命科学研究促进奖-“秋实”季 卓越贡献奖

2023年 川渝科技学术大会优秀论文 特等奖 (排名第三)

 

1. 国家自然科学基金 (面上项目)，糖异生代谢酶PCK1上调组蛋白H3K9me3修饰抑制肝癌的机制研究

2. 国家重点研发计划（子任务），代谢重塑在HBV致病性中的作用机制研究

3. 国家自然科学基金 (面上项目)，PCK1通过降低O-GlcNAc糖基化修饰抑制肝癌转移的机制研究

4. 国家自然科学基金 (青年基金)，PCK1通过Wnt信号通路抑制肝细胞癌的作用机制研究

5. 重庆医科大学 未来医学青年创新团队发展支持计划，“病毒感染与代谢重塑研究团队”

6. 重庆医科大学“新型冠状病毒肺炎”应急专项，SARS-CoV-2假病毒系统的建立及其在抗病毒药物筛选中的应用

7. 重庆市教委科学技术研究计划（青年项目），PCK1下调β-catenin稳定性抑制肝癌EMT的分子机制研究

8. 重庆市教育委员会雏鹰计划研究项目，糖异生关键酶抑制肝癌细胞增殖和迁移能力初探

9. 重庆市自然科学基金（面上项目），PCK1降低Snail1蛋白O-GlcNAc修饰抑制肝癌转移的机制研究 

 

 

1. Zhongqi Feng^#, Jiaxin Yin^#, Zhirong Zhang^#, Zhen Chen, Luyi Huang*, Ni Tang*, Kai Wang*, O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation. Oncogene, 2024. (IF=8) 

2. Dan Nie^#, Xin Tang^#, Haijun Deng^#, Xiaojun Yang^#, Junji Tao, Fengli Xu, Yi Liu, Kang Wu, Kai Wang*, Zhechuan Mei*, Ailong Huang*, Ni Tang*, Metabolic enzyme SLC27A5 regulates PIP4K2A pre-mRNA splicing as a noncanonical mechanism to suppress hepatocellular carcinoma metastasis. Advanced Science, 2024. (IF=15.1)

3. Rui Liu^#, Yi Liu^#, Wenlu Zhang^#, Guiji Zhang^#, Zhirong Zhang, Luyi Huang, Ni Tang*, Kai Wang*, PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. Genes & Diseases, 2024. (IF= 6.8) 

4. De-ao Gong^#, Peng Zhou^#, Wen-yi Chang^#, Jia-yao Yang, Yan-lai Zhang, Ai-long Huang, Ni Tang*, Kai Wang*, SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer. Biochimica et Biophysica Acta - Molecular Cell Research. 2024. (IF= 5.1) 

5. Peng Zhou^#, Wen-yi Chang^#, De-ao Gong^#, Jie Xia^#, Wei Chen, Lu-yi Huang, Rui Liu, Yi Liu, Chang Chen, Kai Wang*, Ni Tang*, Ai-long Huang*, High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate.Cell Metabolism, 2023. (*Co-corresponding author, IF=29) 
   

6. Dongmei Gou^#, Rui Liu^#, Xiaoqun Shan^#, Haijun Deng^#, Chang Chen^#, Jin Xiang, Yi Liu, Qingzhu Gao, Zhi Li, Ailong Huang*, Kai Wang*, Ni Tang*, Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. Journal of Clinical Investigation, 2023. (*Co-corresponding author, IF=19.4) 

7. Qian Ye^#, Yi Liu^#, Guiji Zhang^#, Haijun Deng^#, Xiaojun Wang^#, Lin Tuo^#, Chang Chen, Xuanming Pan, Kang Wu, Jiangao Fan, Qin Pan, Kai Wang*, Ailong Huang*, Ni Tang*, Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice. Nature Communications, 2023. (*Co-corresponding author, IF=17.6)

8. Jin Xiang^#, Chang Chen^#, Rui Liu^#, Dongmei Gou^#, Lei Chang, Haijun Deng, Qingzhu Gao, Wanjun Zhang, Lin Tuo, Xuanming Pan, Li Liang, Jie Xia, Luyi Huang, Ke Yao, Bohong Wang, Zeping Hu, Ailong Huang*, Kai Wang*, Ni Tang*, Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. Journal of Clinical Investigation, 2021. (*Co-corresponding author, IF=19.4)

9. Yang Yang^#, Yu Yan^#, Jiaxin Yin^#, Ni Tang^#, Kai Wang^#, Luyi Huang, Jie Hu, Zhongqi Feng, Qingzhu Gao, Ailong Huang*, O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal Transduction and Targeted Therapy, 2023.  (^#Co-first author, IF=38.1)

10. Peng Zhou^#, Wen-yi Chang^#, De-ao Gong^#, Lu-yi Huang, Rui Liu, Yi Liu, Jie Xia, Kai Wang*, Ni Tang*, Ai-long Huang*, O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene, 2023.  (*Co-corresponding author, IF=8.8)

11. Huating Luo^#, Qiujie Wang^#, Fan Yang^#, Rui Liu^#, Qingzhu Gao^#, Bin Cheng, Xue Lin, Luyi Huang, Chang Chen, Jin Xiang, Kai Wang*, Bo Qin*, Ni Tang*, Signaling metabolite succinylacetone activates HIF-1α and promotes angiogenesis in GSTZ1-deficient hepatocellular carcinoma. JCI Insight. 2023, (IF= 8) 

12. Rui Liu^#, Dongmei Gou^#, Jin Xiang^#, Xuanming Pan, Qingzhu Gao, Peng Zhou, Yi Liu, Jie Hu, Kai Wang*, Ni Tang*, O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis. Oncogene, 2021. (*Co-corresponding author, IF=8.8) 

13. Qingzhu Gao^#, Bin Cheng^#, Chang Chen^#, Chong Lei^#, Xue Lin, Dan Nie, Jingjing Li, Luyi Huang, Xiaosong Li, Kai Wang*, Ailong Huang*, Ni Tang*, Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signaling pathway. Clinical and Translational Medicine, 2022.  (*Co-corresponding author, IF=8.5)

14. Binli Mao^#, Vu Thuy Khanh Le-Trilling^#, Kai Wang^#, Denise Mennerich, Jie Hu, Zhenyu Zhao, Jiaxin Zheng, Yingying Deng, Benjamin Katschinski, Shilei Xu, Guiji Zhang, Xuefei Cai, Yuan Hu, Jianwei Wang, Mengji Lu, Ailong Huang*, Ni Tang*, Mirko Trilling*, Yong Lin*，Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. Emerging Microbes & Infections, 2022. (Co-first author, IF=19.5)

15. Jie Hu^#, Xiao-yu Wei^#, Jin Xiang^#, Pai Peng, Feng-li Xu, Kang Wu, Fei-yang Luo, Ai-shun Jin, Liang Fang, Bei-zhong Liu*, Kai Wang*, Ni Tang*, Ai-Long Huang*, Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Genes & Diseases, 2022.  (*Co-corresponding author，IF=7.2)

16. Pai Peng^#, Hai-jun Deng^#, Jie Hu^#, Xiao-yu Wei, Jian-jiang Xue, Ting-ting Li, Liang Fang, Bei-zhong Liu, Ai-shun Jin, Feng-li Xu, Kang Wu, Quan-xin Long, Juan Chen, Kai Wang*, Ni Tang*, Ai-long Huang*, Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine. Cell Discovery, 2021. (*Co-corresponding author, IF= 38.0)

17. Qiujie Wang^#, Bin Cheng^#, Qiang Xue^#, Qingzhu Gao, Ailong Huang*, Kai Wang*, Ni Tang*, GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death & Disease, 2021. (*Co-corresponding author, IF=9.6)

18. Yi Liu^#, Haijun Deng^#, Li Liang, Guiji Zhang, Jie Xia, Keyue Ding, Ni Tang*, Kai Wang*, Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway. Genes & Diseases, 2021. (*Co-corresponding author，IF=7.2)

19. Chang-Long He^#, Lu-Yi Huang^#, Kai Wang^#, Chen-Jian Gu, Jie Hu, Gui-Ji Zhang, Wei Xu, You-Hua Xie*, Ni Tang*, Ai-Long Huang*, Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. Signal Transduction and Targeted Therapy, 2021. (^#Co-first author, IF=38.1)

20. Jie Hu^# , Pai Peng^#, Kai Wang^#, Liang Fang, Fei-yang Luo, Ai-shun Jin, Bei-zhong Liu*, Ni Tang*, Ai-long Huang*, Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cellular & Molecular Immunology, 2021. (^#Co-first author, IF=22)

21. Pai Peng^#, Jie Hu^#, Hai-jun Deng, Bei-zhong Liu, Liang Fang, Kai Wang*, Ni Tang*, Ai-long Huang*, Changes of humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cellular & Molecular Immunology, 2021. (*Co-corresponding author, IF=22.0)
    

22. Jie Hu^#, Qingzhu Gao^#, Changlong He, Ailong Huang, Ni Tang*, Kai Wang*, Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes & Diseases, 2020. (*Corresponding author，IF=7.1)

23. Jie Hu^#, Qingzhu Gao^#, Yang Yang^#, Jie Xia^#, Wanjun Zhang, Yao Chen, Zhi Zhou, Lei Chang, Yuan Hu, Hui Zhou, Li Liang, Xiaosong Li, Quanxin Long, Kai Wang*, Ailong Huang*, Ni Tang*, Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation. Theranostics, 2021. (*Co-corresponding author, IF=11.5)

24. Qingzhu Gao^#, Guiji Zhang^#, Yaqiu Zheng^#, Yi Yang^#, Chang Chen, Jie Xia, Li Liang, Chong Lei, Yuan Hu, Xue-Fei Cai, Wenlu Zhang, Hua Tang, Yaxi Chen, Ailong Huang*, Kai Wang*, Ni Tang*, SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. Cell Death & Differentiation, 2020.  (*Co-corresponding author, IF=15.8) 

25. Fan Yang^#, Jingjing Li^#, Haijun Deng^#, Yihao Wang, Chong Lei, Qiujie Wang, Jin Xiang, Li Liang, Jie Xia, Xuanming Pan, Xiaosong Li, Quanxin Long, Lei Chang, Ping Xu, Ailong Huang*, Kai Wang*, Ni Tang*, GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone. The EMBO Journal, 2019. (*Co-corresponding author, IF=11.5)  

26. Guiji Zhang^#, Xia Tang^#, Li Liang^#, Wanfeng Zhang, Dewei Li, Xiaoyuan Li, Dachun Zhao, Yaqiu Zheng, Yanhong Chen, Bingtao Hao, Kai Wang*, Ni Tang*, Keyue Ding*, DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma, Oncogene, 2020. (*Co-corresponding author, IF=9.8)  

27. Jin Xiang^#, Yuhong Zhang^#, Lin Tuo, Rui Liu, Dongmei Gou, Li Liang, Chang Chen, Jie Xia, Ni Tang, Kai Wang*, Transcriptomic changes associated with PCK1 overexpression in hepatocellular carcinoma cells detected by RNA-Seq. Genes & Diseases, 2020. (Corresponding author，IF=7.1)

28. Chong Lei^#, Qiujie Wang, Ni Tang*, Kai Wang*, GSTZ1-1 downregulates Wnt/β-catenin signalling in hepatocellular carcinoma cells. FEBS Open Bio, 2020. (Corresponding author，IF=2.7)

29. Jingjing Li^#, Qiujie Wang^#, Yi Yang, Chong Lei, Fan Yang, Li Liang, Chang Chen, Jie Xia, Kai Wang*, Ni Tang*, GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway. Journal of Experimental & Clinical Cancer Research, 2019. (*Co-corresponding author, IF=11.1)

30. Xuemei Chen^#, Yuan Hu^#, Wenlu Zhang, Ke Chen, Jie Hu, Xiaosong Li, Li Liang, Xuefei Cai, Jieli Hu, Kai Wang*, Ailong Huang*, Ni Tang*, Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radical Biology and Medicine, 2019. (*Co-corresponding author, IF=7.376)

31. Lin Tuo^#, Jin Xiang^#, Xuanming Pan^#, Jieli Hu, Hua Tang, Li Liang, Jie Xia, Yuan Hu, Wenlu Zhang, Ailong Huang*, Kai Wang*, Ni Tang*, PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27^Kip1 axis. Journal of Experimental & Clinical Cancer Research, 2019.(*Co-corresponding author, IF=11.161)  

32. Lin Tuo^#, Jin Xiang^#, Xuanming Pan, Qingzhu Gao, Guiji Zhang, Yi Yang, Li Liang, Jie Xia, Kai Wang*, Ni Tang*, PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway. Frontiers in Oncology, 2018. (*Co-corresponding author, IF=6.2)

33. Kai Wang^#, Quan-Xin Long^#, Hai-Jun Deng^#, Jie Hu^#, Qing-Zhu Gao, Gui-Ji Zhang, Chang-long He, Lu-Yi Huang, Jie-li Hu, Juan Chen*, Ni Tang*, Ai-Long Huang*, Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clinical Infectious Diseases, 2021. (First author, IF=20.9)

34. Kai Wang^#, Wei Lv^#, Jianfei Chen^#, Shiqi Xie, Hongyan Shi, Haojen Hsu, Wenjing Yu, Ke Xu, Chao Bian, Wolfgang B Fischer, Wolfgang Schwarz, Li Feng*, Bing Sun*, PEDV ORF3 encodes an ion channel protein and regulates virus production. FEBS Letters, 2012.  (First author)

35. Kai Wang^#, Shiqi Xie, Bing Sun*. Viral proteins function as ion channels. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2011.  (First author)

36. Shiqi Xie^#, Kai Wang^#, Wenjing Yu, Wei Lv, Ke Xu, Jianwei Wang, Bin Ye, Wolfgang Schwarz, Qi Jin*, Bing Sun*, DIDS blocks a chloride-dependent current that is mediated by the 2B protein of enterovirus 71, Cell Research, 2011. (^#Co-first author)

37. Ronghua Zhang^#, Kai Wang^#, Wei Lv^#, Wenjing Yu, Shiqi Xie, Ke Xu, Wolfgang Schwarz, Sidong Xiong*, Bing Sun*, The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2014. (^#Co-first author)

38. Qingzhu Gao^#, Kai Wang^#, Ke Chen, Li Liang, Yaqiu Zheng, Yunzhi Zhang, Jin Xiang, Ni Tang *, HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. Cancer Science, 2017. (^#Co-first author)

39. Ronghua Zhang^#, Kai Wang, Xianqiang Ping, Wenjing Yu, Zhikang Qian, Sidong Xiong*, Bing Sun*, The ns12. 9 accessory protein of human coronavirus OC43 is a viroporin involved in virion morphogenesis and pathogenesis. Journal of Virology, 2015.

40. Silvia Schwarz^#, Kai Wang, Wenjing Yu, Bing Sun, Wolfgang Schwarz*, Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Research, 2011.

41. 向进，庹琳，高庆祝，杨翼，梁利，夏杰，唐霓，汪凯^*. PCK1影响肝癌细胞迁移能力的研究. 重庆医科大学学报, 2018.

42. 潘璇明，张桂冀，陈雪梅，梁利，唐霓，汪凯^*. 果糖-1，6-二磷酸酶1抑制肝癌细胞株HepG2的自噬及增殖. 中华肝脏病杂志, 2019.

43. 龚德敖，唐霓，汪凯^*. 斑点型锌指结构蛋白在肿瘤中的作用. 生命的化学，2022.

44. 杨佳瑶，唐霓，汪凯^*.己糖胺生物合成途径代谢酶与OGT介导的O-GlcNAc修饰在肿瘤中的研究进展.重庆医科大学学报,2023.

 

1. 汪凯，唐霓，庹琳，向进，潘璇明. 6-重氮-5-氧代-L-正亮氨酸在制备预防或治疗肝癌药物中的应用，申请号 CN201811063773.9

2. 汪凯，唐霓，聂丹，唐鑫.一种肝癌组织中 PIP4K2A 剪接变异体的应用，申请号 CN202310059552.9

3. 唐霓，汪凯，黄爱龙，夏杰 等. 氨基氧乙酸在制备治疗肝细胞肝癌的药物中的应用，授权号 ZL201910064794.0
   

4. 唐霓，汪凯，高庆祝，陈昶 等. 尿苷二磷酸葡萄糖醛酸在制备用于检测肝癌试剂中的应用，申请号 CN202210860675.8
   

5. 黄露义，唐霓，汪凯，黄爱龙，何长龙. 双苄四氢异喹啉衍生物在制备抗冠状病毒药物中的应用, 授权号 ZL202011375253.9
   

6. 黄露义，唐霓，汪凯，黄爱龙，杨泱. N-磺酰基杂环衍生物及其制药用途, 申请号 CN202011640906.1

7. 黄露义，唐霓，汪凯，黄爱龙，单晓群. 一种新型O-GlcNAc转移酶抑制剂及其用途  申请号 CN202211102591.4
   

8. 夏杰，黄爱龙，刘迪娜，唐霓，汪凯，蔡莹 等. 一种肝纤维化或肝硬化的诊断试剂盒， 申请号 CN201911315897.6
   

9. 林永，毛彬力，黄爱龙，唐霓，汪凯，赵珍玉 等. 二叶草素在制备抗新型冠状病毒的药物中的用途, 申请号CN202110092946.5